Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration

Sponsor
Instituto de Olhos de Goiania
Study ID
NCT00556348
Phase
PHASE4
Status
Completed

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

Study Details

To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Roche, Rio de Janeiro, Brazil) in patients with choroidal neovascularization secondary to age-related macular degeneration.

Key Dates

First listed
Nov 12, 2007
Start date
Nov 30, 2005
Status verified
Nov 2011
Primary completion
Oct 31, 2007
Completion
Nov 30, 2008

Study Design

Enrollment
500 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Vision change Anatomical changes (Regression of NVE, CNVM, reduction in macular thickness) Electrophysiological changes (ERG, VEP

Related Studies